Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016

  • ID: 4030252
  • Report
  • 35 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cognosci Inc
  • Genzyme Corp
  • MedImmune LLC
  • MORE
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Progressive Relapsing Multiple Sclerosis - Pipeline Review, H2 2016, provides an overview of the Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline landscape.

Progressive-relapsing multiple sclerosis (PRMS) refers to a pattern of relapses within primary-progressive MS (PPMS). Signs of PRMS include muscle spasms, weak muscles, dizziness, chronic pain and vision changes. Risk factors include age, family history, autoimmune diseases and smoking. Treatment includes immunosuppressant drugs.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Progressive Relapsing Multiple Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Relapsing Multiple Sclerosis (PRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 3 respectively.

Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Relapsing Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cognosci Inc
  • Genzyme Corp
  • MedImmune LLC
  • MORE
Introduction

Progressive Relapsing Multiple Sclerosis (PRMS) Overview

Therapeutics Development

Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Overview

Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Development by Companies

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Development by Companies

Progressive Relapsing Multiple Sclerosis (PRMS) - Companies Involved in Therapeutics Development

Cognosci Inc

Genzyme Corp

MedImmune LLC

VivaCell Biotechnology Espana SL

Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

COG-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COG-133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-402668 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inebilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCE-0032 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects

Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by Cognosci Inc, H2 2016

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by Genzyme Corp, H2 2016

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by MedImmune LLC, H2 2016

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by VivaCell Biotechnology Espana SL, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects, H2 2016

Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016

Number of Products under Development by Companies, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Cognosci Inc
  • Genzyme Corp
  • MedImmune LLC
  • VivaCell Biotechnology Espana SL
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll